Bayer Presents New Study Results for Xarelto
30 Março 2020 - 3:54AM
Dow Jones News
By Kim Richters
Bayer AG over the weekend presented two new studies and results
for its blood thinner Xarelto.
The German pharmaceutical and chemical company said the drug
plus aspirin reduces the combined risk of limb ischemia and major
cardiovascular events for patients who have a symptomatic
peripheral artery disease after revascularization.
The results are from the Phase 3 VOYAGER PAD study, the company
said.
Another study showed that Xarelto lowers the risk of major
venous thromboembolism after minor orthopaedic surgery, Bayer
said.
This data is from the from the clinical Phase 3 trial PRONOMOS,
it said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 30, 2020 02:39 ET (06:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
